Pentavalent vaccine and Salk IPV

Vaccine

LLG Chem

Pentavalent vaccine and Salk IPV is one of 31 biologic programs targeting Hepatitis B. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatitis BActive, not recruiting

Hepatitis BPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Hepatitis B

#DrugCompanyPhaseTrials

Viread

Gilead

Phase 3

4 2

YF-Vax

Sanofi

Phase 3

1 3

Virazole

CConrado Roberto Hoffmann Filho

Phase 3

3 4

Immunoglobulins

CSL Behring

Phase 3

1 5

Recombinant Hepatitis B Vaccine

Novartis

Phase 3

7 6

Hydronidone

BBeijing Continent Pharmaceutical Co, Ltd.

Phase 3

2 7

Polio Sabin.

GSK

Phase 3

1 8

Hepatitis B Adjuvanted Vaccine

GSK

Phase 3

4 9

HEPLISAV

DDynavax Technologies Corporation

Phase 3

3 10

Vemlidy

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2/3Recruiting

Hepatitis B

NCT06947499

Clinical

Trials by Indication[1]

Immunogenicity2 trials

Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series

Unknown status·LLG Chem·Phase 2/3·NCT05457946·1,438 enrolled

Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants

Unknown status·LLG Chem·Phase 2·NCT04073459·336 enrolled

Hepatitis B1 trial

A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series

Recruiting·LLG Chem·Phase 2/3·NCT06947499·1,186 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Pentavalent vaccine and Salk IPV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pentavalent vaccine and Salk IPV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pentavalent vaccine and Salk IPV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LG Chem company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Company: LLG Chem

Pentavalent vaccine and Salk IPV

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Immunogenicity2 trials

Hepatitis B1 trial

References

Drug Info

Quick Facts

Related News